Within metastatic CCRCC, plasma and tissue expression of PD-1 and PD-L1 were analyzed according to the IMDC risk classification and also according to the Morphology, Attenuation, Size and Structure (MASS) response criteria in patients receiving systemic therapy for metastatic disease. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.